Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT07245069

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07245069
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Slovenia (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07245069. Randomized; quadruple masking; primary purpose prevention. Start 2025-02-01 (actual); primary completion 2028-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
Acronym
Alpaca
Condition
Heart Failure
Condition
Anthracycline-induced Cardiac Toxicity
Condition
Endothelial Function (FMD)
Condition
Arterial Stiffness
Condition
Breast Cancer
Intervention (Drug)
Dapagliflozin 10 mg
Intervention (Drug)
Placebo
Lead sponsor
University Medical Centre Ljubljana (class: other)

Record details

Record id
cardio:ct-nct07245069
Content hash
f5967f30cf269ce60f711c0c847aea75382e158e39ccf1fdcd9c408a084d995e